11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`COVID-19 Information
`Public health information (CDC) Research information (NIH) SARS-CoV-2 data (NCBI)
`Prevention and treatment information (HHS) Español
`
`COMPOUND SUMMARY
`
`Treprostinil
`
`PubChem CID
`
`6918140
`
`Structure
`
`Chemical Safety
`
`Molecular Formula
`
`Synonyms
`
`Molecular Weight
`
`Dates
`
`2D
`Find Similar Structures
`
`3D
`
`Acute Toxic Health Hazard
`Laboratory Chemical Safety Summary (LCSS) Datasheet
`
`C H O
`23 34 5
`Treprostinil
`Remodulin
`81846-19-7
`Treprostinil sodium
`Uniprost
`More...
`390.5
`Modify
`2021-11-06
`
`Create
`2006-07-28
`
`Treprostinil is a carboxylic acid and a carbotricyclic compound. It has a role as a platelet aggregation inhibitor, a vasodilator
`agent, an antihypertensive agent, a cardiovascular drug, a vitamin K antagonist and a human blood serum metabolite.
`ChEBI
`
`Treprostinil is a Prostacycline Vasodilator. The physiologic effect of treprostinil is by means of Vasodilation.
`FDA Pharm Classes
`
`Treprostinil is a synthetic analogue of prostacyclin, used to treat pulmonary hypertension.
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`1/43
`
`IPR2021-00406
`United Therapeutics EX2083
`Page 1 of 43
`
`

`

`11/10/21, 2:11 PM
`DrugBank
`
`Treprostinil | C23H34O5 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`2/43
`
`Page 2 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`1 Structures
`1.1 2D Structure
`
`Chemical Structure
`Depiction
`
`PubChem
`
`1.2 3D Conformer
`
`PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`3/43
`
`Page 3 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`2 Names and Identifiers
`2.1 Computed Descriptors
`
`2.1.1 IUPAC Name
`2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
`Computed by Lexichem TK 2.7.0 (PubChem release 2021.05.07)
`PubChem
`
`2.1.2 InChI
`InChI=1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-
`19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1
`Computed by InChI 1.0.6 (PubChem release 2021.05.07)
`PubChem
`
`2.1.3 InChI Key
`PAJMKGZZBBTTOY-ZFORQUDYSA-N
`Computed by InChI 1.0.6 (PubChem release 2021.05.07)
`PubChem
`
`2.1.4 Canonical SMILES
`CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O
`Computed by OEChem 2.3.0 (PubChem release 2021.05.07)
`PubChem
`
`2.1.5 Isomeric SMILES
`CCCCC[C@@H](CC[C@H]1[C@@H](C[C@H]2[C@@H]1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O
`Computed by OEChem 2.3.0 (PubChem release 2021.05.07)
`PubChem
`
`2.2 Molecular Formula
`C23H34O5
`Computed by PubChem 2.1 (PubChem release 2021.05.07)
`PubChem
`
`2.3 Other Identifiers
`2.3.1 CAS
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`4/43
`
`Page 4 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`81846-19-7
`CAS Common Chemistry; ChemIDplus; DrugBank; Human Metabolome Database (HMDB)
`
`289480-64-4
`ChemIDplus
`
`2.3.2 Related CAS
`289480-64-4 (Sodium salt)
`ChemIDplus
`
`81846-19-7 (Parent)
`ChemIDplus
`
`2.3.3 UNII
`RUM6K67ESG
`FDA/SPL Indexing Data
`
`2.3.4 Wikipedia
`Treprostinil sodium
`Wikipedia
`
`Treprostinil
`Wikipedia
`
`2.4 Synonyms
`
`2.4.1 MeSH Entry Terms
`
`((1R,2R,3AS,9AS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3A,4,9,9A-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate
`Orenitram
`Remodulin
`trepostinil sodium
`treprostinil
`treprostinil diethanolamine
`treprostinil diolamin
`treprostinil diolamine
`treprostinil sodium
`UT-15
`UT-15C
`
`Medical Subject Headings (MeSH)
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`5/43
`
`Page 5 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`2.4.2 Depositor-Supplied Synonyms
`
`Treprostinil
`Remodulin
`81846-19-7
`Treprostinil sodium
`Uniprost
`Orenitram
`Rumodolin
`UT-15
`LRX-15
`Tyvaso
`Treprostinil free acid
`15AU81
`
`UNII-RUM6K67ESG
`RUM6K67ESG
`2-(((1R,2R,3aS,9aS)-2-hydroxy-1-((S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl)oxy)a
`CHEBI:50861
`81846-19-7 (free acid)
`289480-64-4
`treprostinilo
`treprostinilum
`LRX 15
`Treprostinil [USAN:INN]
`Remodulin (TN)
`U 62840
`
`PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`6/43
`
`Page 6 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`3 Chemical and Physical Properties
`3.1 Computed Properties
`
`Property Name
`
`Property Value
`
`Reference
`
`390.5
`4.5
`3
`5
`10
`390.24062418
`390.24062418
`87 Ų
`28
`0
`495
`0
`5
`0
`0
`0
`1
`Yes
`
`Computed by PubChem 2.1 (PubChem release 2021.05.07)
`Computed by XLogP3 3.0 (PubChem release 2021.05.07)
`Computed by Cactvs 3.4.8.18 (PubChem release 2021.05.07)
`Computed by Cactvs 3.4.8.18 (PubChem release 2021.05.07)
`Computed by Cactvs 3.4.8.18 (PubChem release 2021.05.07)
`Computed by PubChem 2.1 (PubChem release 2021.05.07)
`Computed by PubChem 2.1 (PubChem release 2021.05.07)
`Computed by Cactvs 3.4.8.18 (PubChem release 2021.05.07)
`Computed by PubChem
`Computed by PubChem
`Computed by Cactvs 3.4.8.18 (PubChem release 2021.05.07)
`Computed by PubChem
`Computed by PubChem
`Computed by PubChem
`Computed by PubChem
`Computed by PubChem
`Computed by PubChem
`Computed by PubChem (release 2021.05.07)
`
`Molecular Weight
`XLogP3-AA
`Hydrogen Bond Donor Count
`Hydrogen Bond Acceptor Count
`Rotatable Bond Count
`Exact Mass
`Monoisotopic Mass
`Topological Polar Surface Area
`Heavy Atom Count
`Formal Charge
`Complexity
`Isotope Atom Count
`Defined Atom Stereocenter Count
`Undefined Atom Stereocenter Count
`Defined Bond Stereocenter Count
`Undefined Bond Stereocenter Count
`Covalently-Bonded Unit Count
`Compound Is Canonicalized
`
`PubChem
`
`3.2 Experimental Properties
`
`3.2.1 Physical Description
`Solid
`
`Human Metabolome Database (HMDB)
`
`3.2.2 Solubility
`Insoluble at 25°C
`DrugBank
`
`7.31e-03 g/L
`Human Metabolome Database (HMDB)
`
`3.2.3 LogP
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`7/43
`
`Page 7 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`DrugBank
`
`4.1
`
`4.1
`
`Human Metabolome Database (HMDB)
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`8/43
`
`Page 8 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`4 Spectral Information
`4.1 Mass Spectrometry
`
`1118146
`IT/ion trap
`0
`MS2
`[M-H]-
`389.2333
`6
`331.3
`345.3
`327.4
`
`4.1.1 MS-MS
`
`NIST Number
`Instrument Type
`Collision Energy
`Spectrum Type
`Precursor Type
`Precursor m/z
`Total Peaks
`m/z Top Peak
`m/z 2nd Highest
`m/z 3rd Highest
`
`Thumbnail
`
`NIST Mass Spectrometry Data Center
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`9/43
`
`Page 9 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`5 Related Records
`5.1 Related Compounds with Annotation
`
`PubChem
`
`5.2 Related Compounds
`Same Connectivity
`61 Records
`Same Stereo
`23 Records
`Same Isotope
`31 Records
`Same Parent, Connectivity
`88 Records
`Same Parent, Stereo
`37 Records
`Same Parent, Isotope
`57 Records
`Same Parent, Exact
`14 Records
`Mixtures, Components, and
`Neutralized Forms
`Similar Compounds
`Similar Conformers
`
`19 Records
`
`1,323 Records
`28 Records
`
`PubChem
`
`5.3 Substances
`
`5.3.1 Related Substances
`
`All
`Same
`Mixture
`
`PubChem
`
`183 Records
`92 Records
`91 Records
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`10/43
`
`Page 10 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`5.3.2 Substances by Category
`
`PubChem
`
`5.4 Entrez Crosslinks
`PubMed
`58 Records
`Taxonomy
`2 Records
`OMIM
`1 Record
`Gene
`3 Records
`
`PubChem
`
`5.5 NCBI LinkOut
`
`NCBI
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`11/43
`
`Page 11 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`12/43
`
`Page 12 of 43
`
`

`

`11/10/21, 2:11 PM
`
`6 Chemical Vendors
`
`Treprostinil | C23H34O5 - PubChem
`
`PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`13/43
`
`Page 13 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`7 Drug and Medication Information
`7.1 Drug Indication
`
`Showing 3 of 4 View More
`
`For use as a continuous subcutaneous infusion or intravenous infusion (for those not able to tolerate a subcutaneous infusion)
`for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms
`associated with exercise.
`DrugBank
`
`FDA Label
`DrugBank
`
`Treatment of adult patients with WHO Functional Class (FC) III or IV and:, , , inoperable chronic thromboembolic pulmonary
`hypertension (CTEPH), or, persistent or recurrent CTEPH after surgical treatment, , , to improve exercise capacity.,
`European Medicines Agency (EMA)
`
`7.2 FDA Orange Book
`
`FDA Drugs
`
`7.3 Drug Labels for Ingredients
`Label Information
`Total 7 labels
`Drug Ingredient
`TREPROSTINIL
`0703-0666-01, 0703-0676-01, 0703-0686-01, 0703-0696-01, 0781-3420-80, 0781-3425-80, 0781-3427-80,
`0781-3430-80, 0781-6021-94, 42023-206-01 ... total 42.
`Alembic Pharmaceuticals Inc.; Par Pharmaceutical, Inc.; Sandoz Inc; Teva Parenteral Medicines, Inc.; United
`Therapeutics Corporation
`
`NDC Code(s)
`
`Packagers
`
`DailyMed
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`14/43
`
`Page 14 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`7.4 Clinical Trials
`
`7.4.1 ClinicalTrials.gov
`
`ClinicalTrials.gov
`
`7.4.2 EU Clinical Trials Register
`
`EU Clinical Trials Register
`
`7.4.3 NIPH Clinical Trials Search of Japan
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`15/43
`
`Page 15 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`NIPH Clinical Trials Search of Japan
`
`7.5 EMA Drug Information
`
`Showing 2 of 3 View More
`
`Medicine
`Therapeutic area
`Active Substance
`INN/Common name
`Pharmacotherapeutic
`Classes
`Status
`Company
`Market Date
`
`Trepulmix
`Hypertension, Pulmonary
`Treprostinil sodium
`treprostinil
`
`Antithrombotic agents
`
`This medicine is authorized for use in the European Union
`SciPharm Sàrl
`2020-04-03
`
`European Medicines Agency (EMA)
`
`Medicine
`Disease/Condition
`Active Substance
`Status of Orphan
`Designation
`Decision Date
`
`Tyvaso
`Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
`Treprostinil sodium
`
`Positive
`
`2004-04-14
`
`European Medicines Agency (EMA)
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`16/43
`
`Page 16 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`8 Pharmacology and Biochemistry
`8.1 Pharmacology
`Pulmonary arterial hypertension (PAH) is a disease in which blood pressure is abnormally high in the arteries between the heart
`and lungs. PAH is characterized by symptoms of shortness of breath during physical exertion. The condition can ultimately lead
`to heart failure. Treprostinil is a potent oral antiplatelet agent. The major pharmacologic actions of treprostinil are direct
`vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In animals, the vasodilatory
`effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. Other studies have shown that
`treprostinil causes a dose-related negative inotropic and lusitropic effect. No major effects on cardiac conduction have been
`observed.
`DrugBank
`
`8.2 MeSH Pharmacological Classification
`Antihypertensive Agents
`Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the
`antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC
`ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC
`BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
`Medical Subject Headings (MeSH)
`
`8.3 FDA Pharmacological Classification
`FDA UNII
`RUM6K67ESG
`Active Moiety
`TREPROSTINIL
`Pharmacological Classes
`Established Pharmacologic Class [EPC] - Prostacycline Vasodilator
`Pharmacological Classes
`Chemical Structure [CS] - Prostaglandins I
`Pharmacological Classes
`Physiologic Effects [PE] - Vasodilation
`FDA Pharmacology
`Summary
`
`Treprostinil is a Prostacycline Vasodilator. The physiologic effect of treprostinil is by means of Vasodilation.
`
`FDA Pharm Classes
`
`8.4 ATC Code
`B01AC21
`European Medicines Agency (EMA)
`
`B - Blood and blood forming organs
`B01 - Antithrombotic agents
`B01A - Antithrombotic agents
`B01AC - Platelet aggregation inhibitors excl. heparin
`B01AC21 - Treprostinil
`WHO Anatomical Therapeutic Chemical (ATC) Classification
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`17/43
`
`Page 17 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`8.5 Absorption, Distribution and Excretion
`Absorption
`Relatively rapid and complete after subcutaneous infusion, with an absolute bioavailability approximately 100%. In patients with
`mild (n=4) or moderate (n=5) hepatic insufficiency and portopulmonary hypertension following a subcutaneous dose of 10 ng
`per kg of body weight per min for 150 mins the AUC 0-∞ was increased 3-fold and 5-fold respectively.
`DrugBank
`
`Volume of Distribution
`14 L/70 kg
`DrugBank
`
`8.6 Metabolism/Metabolites
`Substantially metabolized by the liver, but the precise enzymes responsible are unknown. Five metabolites have been described
`(HU1 through HU5) however, the biological activity and metabolic fate of these are unknown. The chemical structure of HU1 is
`unknown. The metabolite HU5 is the glucuronide conjugate of treprostinil. The other metabolites are formed by oxidation of the
`3-hydroxyoctyl side chain (HU2) and subsequent additional oxidation (HU3) or dehydration (HU4). Study results of in vitro
`human hepatic cytochrome P450 demonstrates that treprostinil does not inhibit CYP-1A2, 2C9, 2C19, 2D6, 2E1, or 3A. There
`have been no studies that evaluate the potential of treprostinil to induce these enzymes.
`DrugBank
`
`8.7 Biological Half-Life
`Terminal elimination half-life is approximately 2 to 4 hours. Plasma half-life is 34 and 85 minutes for intravenous and
`subcutaneous infusion of the drug, respectively.
`DrugBank
`
`8.8 Mechanism of Action
`The major pharmacological actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and
`inhibition of platelet aggregation. In addition to treprostinil's direct vasodilatory effects, it also inhibits inflammatory cytokine. As
`a synthetic analogue of prostacyclin, it binds to the prostacyclin receptor, which subsequently induces the aforementioned
`downstream effects.
`DrugBank
`
`8.9 Human Metabolite Information
`
`8.9.1 Cellular Locations
`
`Cytoplasm
`Membrane
`
`Human Metabolome Database (HMDB)
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`18/43
`
`Page 18 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`9 Use and Manufacturing
`9.1 Use Classification
`Human drugs -> Orphan -> Trepulmix -> EMA Drug Category
`European Medicines Agency (EMA)
`
`Antithrombotic agents -> Human pharmacotherapeutic group
`European Medicines Agency (EMA)
`
`Human drugs -> Rare disease (orphan)
`European Medicines Agency (EMA)
`
`Human Drugs -> EU pediatric investigation plans
`European Medicines Agency (EMA)
`
`Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients
`FDA Drugs
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`19/43
`
`Page 19 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`10 Safety and Hazards
`10.1 Hazards Identification
`
`10.1.1 GHS Classification
`
`Showing 1 of 2 View More
`
`Pictogram(s)
`
`Signal
`
`GHS Hazard Statements
`
`
`Acute Toxic Health Hazard
`Danger
`H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]
`H311 (66.67%): Toxic in contact with skin [Danger Acute toxicity, dermal]
`H331 (66.67%): Toxic if inhaled [Danger Acute toxicity, inhalation]
`H361 (66.67%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
`
`Precautionary Statement
`Codes
`
`P201, P202, P261, P264, P270, P271, P280, P281, P301+P310, P302+P352, P304+P340, P308+P313, P311, P312,
`P321, P322, P330, P361, P363, P403+P233, P405, and P501
`(The corresponding statement to each P-code can be found at the GHS Classification page.)
`
`ECHA C&L Notifications
`Summary
`
`Aggregated GHS information provided by 4 companies from 3 notifications to the ECHA C&L Inventory. Each
`notification may be associated with multiple companies.
`Reported as not meeting GHS hazard criteria by 1 of 4 companies. For more detailed information, please visit
`ECHA C&L website.
`Of the 2 notification(s) provided by 3 of 4 companies with hazard statement code(s).
`Information may vary between notifications depending on impurities, additives, and other factors. The
`percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard
`codes. Only hazard codes with percentage values above 10% are shown.
`
`European Chemicals Agency (ECHA)
`
`10.1.2 Hazard Classes and Categories
`Acute Tox. 3 (100%)
`Acute Tox. 3 (66.67%)
`Acute Tox. 3 (66.67%)
`Repr. 2 (66.67%)
`European Chemicals Agency (ECHA)
`
`Acute Tox. 3 (100%)
`Acute Tox. 3 (50%)
`Skin Irrit. 2 (50%)
`Eye Irrit. 2 (50%)
`Acute Tox. 3 (50%)
`STOT SE 3 (50%)
`Repr. 2 (50%)
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`20/43
`
`Page 20 of 43
`
`

`

`11/10/21, 2:11 PM
`STOT RE 1 (50%)
`European Chemicals Agency (ECHA)
`
`Treprostinil | C23H34O5 - PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`21/43
`
`Page 21 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`11 Toxicity
`11.1 Toxicological Information
`
`11.1.1 Toxicity Summary
`Symptoms of overdose are extensions of its dose-limiting pharmacologic effects and include flushing, headache, hypotension,
`nausea, vomiting, and diarrhea. Most events were self-limiting and resolved with reduction or withholding of treprostinil.
`DrugBank
`
`11.1.2 Protein Binding
`Human plasma protein binding is approximately 91% in in vitro concentrations ranging from 330 to 10,000 µ/L.
`DrugBank
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`22/43
`
`Page 22 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`12 Associated Disorders and Diseases
`
`Comparative Toxicogenomics Database (CTD)
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`23/43
`
`Page 23 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`13 Literature
`13.1 Coronavirus Studies
`
`PubChem
`
`13.2 NLM Curated PubMed Citations
`
`PubChem
`
`13.3 Springer Nature References
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`24/43
`
`Page 24 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`Springer Nature
`
`13.4 Thieme References
`
`Thieme Chemistry
`
`13.5 Depositor Provided PubMed Citations
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`25/43
`
`Page 25 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`PubChem
`
`13.6 Synthesis References
`Hitesh Batra, Raju Penmasta, Vijay Sharma, Sudersan M. Tuladhar, David A. Walsh, "TREPROSTINIL PRODUCTION." U.S. Patent
`US20110319641, issued December 29, 2011.
`DrugBank
`
`13.7 Chemical Co-Occurrences in Literature
`
`PubChem
`
`13.8 Chemical-Gene Co-Occurrences in Literature
`
`PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`26/43
`
`Page 26 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`13.9 Chemical-Disease Co-Occurrences in Literature
`
`PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`27/43
`
`Page 27 of 43
`
`

`

`Treprostinil | C23H34O5 - PubChem
`
`US10716793
`US10695308
`
`11/10/21, 2:11 PM
`
`14 Patents
`
`US5153222
`US8653137
`US8658694
`US7999007
`US9199908
`US6765117
`US8497393
`US6521212
`US6756033
`US7544713
`US9278901
`US7417070
`US8410169
`
`DrugBank
`
`US9050311
`US8252839
`US8747897
`US8349892
`US9593066
`US9604901
`US9339507
`US9358240
`US9422223
`US9393203
`US9713599
`US10076505
`US10376525
`
`14.1 Depositor-Supplied Patent Identifiers
`
`PubChem
`
`Link to all deposited patent identifiers
`PubChem
`
`14.2 WIPO PATENTSCOPE
`Patents are available for this chemical structure:
`https://patentscope.wipo.int/search/en/result.jsf?inchikey=PAJMKGZZBBTTOY-ZFORQUDYSA-N
`PATENTSCOPE (WIPO)
`
`14.3 FDA Orange Book Patents
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`28/43
`
`Page 28 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Showing 3 of 24 View More
`
`Treprostinil | C23H34O5 - PubChem
`
`Patent
`Expiration
`Applicant
`Drug Application
`
`FDA Drugs
`
`Patent
`Expiration
`Applicant
`Drug Application
`
`FDA Drugs
`
`Patent
`Expiration
`Applicant
`Drug Application
`
`FDA Drugs
`
`7417070
`Jul 30, 2026
`UNITED THERAP
`N203496 (Prescription Drug: ORENITRAM. Ingredients: TREPROSTINIL DIOLAMINE)
`
`7544713
`Jul 14, 2024
`UNITED THERAP
`N203496 (Prescription Drug: ORENITRAM. Ingredients: TREPROSTINIL DIOLAMINE)
`
`7999007
`Mar 29, 2029
`UNITED THERAP
`N021272 (Prescription Drug: REMODULIN. Ingredients: TREPROSTINIL)
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`29/43
`
`Page 29 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`15 Biomolecular Interactions and Pathways
`15.1 Drug-Gene Interactions
`
`Drug Gene Interaction database (DGIdb)
`
`15.2 Chemical-Gene Interactions
`
`15.2.1 CTD Chemical-Gene Interactions
`
`Comparative Toxicogenomics Database (CTD)
`
`15.3 DrugBank Interactions
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`30/43
`
`Page 30 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`DrugBank
`
`15.4 Drug-Drug Interactions
`
`DrugBank
`
`15.5 Drug-Food Interactions
`Take with food. Taking treprostinil with food increases oral absorption.
`DrugBank
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`31/43
`
`Page 31 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`16 Biological Test Results
`16.1 BioAssay Results
`
`PubChem
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`32/43
`
`Page 32 of 43
`
`

`

`Treprostinil | C23H34O5 - PubChem
`
`11/10/21, 2:11 PM
`
`17 Classification
`17.1 Ontologies
`
`17.1.1 MeSH Tree
`
`Medical Subject Headings (MeSH)
`
`17.1.2 NCI Thesaurus Tree
`
`NCI Thesaurus (NCIt)
`
`17.1.3 ChEBI Ontology
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`33/43
`
`Page 33 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`ChEBI
`
`17.1.4 KEGG: Drug
`
`KEGG
`
`17.1.5 KEGG: USP
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`34/43
`
`Page 34 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`KEGG
`
`17.1.6 KEGG: ATC
`
`KEGG
`
`17.1.7 KEGG: Target-based Classification of Drugs
`
`KEGG
`
`17.1.8 KEGG: Drug Classes
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`35/43
`
`Page 35 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`KEGG
`
`17.1.9 WHO ATC Classification System
`
`WHO Anatomical Therapeutic Chemical (ATC) Classification
`
`17.1.10 FDA Pharm Classes
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`36/43
`
`Page 36 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`FDA Pharm Classes
`
`17.1.11 ChemIDplus
`
`ChemIDplus
`
`17.1.12 Guide to PHARMACOLOGY Target Classification
`
`IUPHAR/BPS Guide to PHARMACOLOGY
`
`17.1.13 ChEMBL Target Tree
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`37/43
`
`Page 37 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`ChEMBL
`
`17.1.14 UN GHS Classification
`
`UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)
`
`17.1.15 NORMAN Suspect List Exchange Classification
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`38/43
`
`Page 38 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`NORMAN Suspect List Exchange
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`39/43
`
`Page 39 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`18 Information Sources
`
`FILTER BY SOURCE
`
`ALL SOURCES
`
`1. CAS Common Chemistry
`LICENSE
`The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated.
`https://creativecommons.org/licenses/by-nc/4.0/
`
`Treprostinil
`https://commonchemistry.cas.org/detail?cas_rn=81846-19-7
`2. ChemIDplus
`LICENSE
`https://www.nlm.nih.gov/copyright.html
`
`Treprostinil [USAN:INN]
`https://chem.nlm.nih.gov/chemidplus/sid/0081846197
`Treprostinil sodium
`https://chem.nlm.nih.gov/chemidplus/sid/0289480644
`ChemIDplus Chemical Information Classification
`https://chem.nlm.nih.gov/chemidplus/
`3. DrugBank
`LICENSE
`Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)
`https://www.drugbank.ca/legal/terms_of_use
`
`Treprostinil
`https://www.drugbank.ca/drugs/DB00374
`4. Human Metabolome Database (HMDB)
`LICENSE
`HMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires
`explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page).
`We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications.
`http://www.hmdb.ca/citing
`
`Treprostinil
`http://www.hmdb.ca/metabolites/HMDB0014518
`5. ChEBI
`Treprostinil
`http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50861
`ChEBI Ontology
`http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology
`6. FDA Pharm Classes
`LICENSE
`Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and
`may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug
`Administration as the source is appreciated but not required.
`https://www.fda.gov/about-fda/about-website/website-policies#linking
`
`TREPROSTINIL
`https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm
`FDA Pharmacological Classification
`https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
`7. ClinicalTrials.gov
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`40/43
`
`Page 40 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`LICENSE
`The ClinicalTrials.gov data carry an international copyright outside the United States and its Territories or Possessions. Some ClinicalTrials.gov data may be
`subject to the copyright of third parties; you should consult these entities for any additional terms of use.
`https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
`
`https://clinicaltrials.gov/
`8. Comparative Toxicogenomics Database (CTD)
`LICENSE
`It is to be used only for research and educational purposes. Any reproduction or use for commercial purpose is prohibited without the prior express
`written permission of the MDI Biological Laboratory and NC State University.
`http://ctdbase.org/about/legal.jsp
`
`http://ctdbase.org/detail.go?type=chem&acc=C427248
`9. DailyMed
`LICENSE
`https://www.nlm.nih.gov/copyright.html
`
`TREPROSTINIL
`https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=TREPROSTINIL
`10. Drug Gene Interaction database (DGIdb)
`LICENSE
`The data used in DGIdb is all open access and where possible made available as raw data dumps in the downloads section.
`http://www.dgidb.org/downloads
`
`https://www.dgidb.org/drugs/TREPROSTINIL
`11. European Medicines Agency (EMA)
`LICENSE
`Information on the European Medicines Agency's (EMA) website is subject to a disclaimer and copyright and limited reproduction notices.
`https://www.ema.europa.eu/en/about-us/legal-notice
`
`Trepulmix (EMEA/H/C/005207)
`https://www.ema.europa.eu/en/medicines/human/EPAR/trepulmix
`Treprostinil (P/0144/2018)
`https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000207-pip01-08-m06
`Treprostinil sodium (EU/3/04/197)
`https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu304197
`12. EU Clinical Trials Register
`https://www.clinicaltrialsregister.eu/
`13. European Chemicals Agency (ECHA)
`LICENSE
`Use of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other
`binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced,
`distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals
`Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and
`individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the
`Legal Notice page.
`https://echa.europa.eu/web/guest/legal-notice
`
`Acetic acid, (((1R,2R,3aS,9aS)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-((3S)-3-hydroxyoctyl)-1H-benz(f)inden-5-yl)oxy)-, monosodium salt
`https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/230635
`(1R, 2R,3aS,9aS)-[[2,3,3a,4,9,9a-Hexahydro-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl]oxy]acetic acid
`https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/245410
`14. FDA Drugs
`LICENSE
`Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and
`may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug
`Administration as the source is appreciated but not required.
`https://www.fda.gov/about-fda/about-website/website-policies#linking
`
`https://www.fda.gov/Drugs/InformationOnDrugs/ucm129662.htm
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`41/43
`
`Page 41 of 43
`
`

`

`11/10/21, 2:11 PM
`Treprostinil | C23H34O5 - PubChem
`15. WHO Anatomical Therapeutic Chemical (ATC) Classification
`LICENSE
`Use of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for
`commercial purposes is not allowed. Changing or manipulating the material is not allowed.
`https://www.whocc.no/copyright_disclaimer/
`
`https://www.whocc.no/atc/
`ATC Code
`https://www.whocc.no/atc_ddd_index/
`16. FDA/SPL Indexing Data
`LICENSE
`Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and
`may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug
`Administration as the source is appreciated but not required.
`https://www.fda.gov/about-fda/about-website/website-policies#linking
`
`RUM6K67ESG
`https://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSystem-UniqueIngredientIdentifierUNII/
`17. NIPH Clinical Trials Search of Japan
`https://rctportal.niph.go.jp/en/
`18. NIST Mass Spectrometry Data Center
`LICENSE
`https://www.nist.gov/srd/public-law
`
`Treprostinil
`http://www.nist.gov/srd/nist1a.cfm
`19. PubChem
`https://pubchem.ncbi.nlm.nih.gov
`20. Springer Nature
`https://pubchem.ncbi.nlm.nih.gov/substance/341212896
`21. Thieme Chemistry
`LICENSE
`The Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated.
`https://creativecommons.org/licenses/by-nc-nd/4.0/
`22. Wikipedia
`treprostinil sodium
`https://www.wikidata.org/wiki/Q18578845
`treprostinil
`https://en.wikipedia.org/wiki/Treprostinil
`23. Medical Subject Headings (MeSH)
`LICENSE
`Works produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of
`Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.
`https://www.nlm.nih.gov/copyright.html
`
`treprostinil
`https://www.ncbi.nlm.nih.gov/mesh/67427248
`MeSH Tree
`http://www.nlm.nih.gov/mesh/meshhome.html
`Antihypertensive Agents
`https://www.ncbi.nlm.nih.gov/mesh/68000959
`24. KEGG
`LICENSE
`Academic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial license
`https://www.kegg.jp/kegg/legal.html
`
`https://pubchem.ncbi.nlm.nih.gov/compound/Treprostinil
`
`42/43
`
`Page 42 of 43
`
`

`

`11/10/21, 2:11 PM
`
`Treprostinil | C23H34O5 - PubChem
`
`Therapeutic category of drugs in Japan
`http://www.genome.jp/kegg-bin/get_htext?br08301.keg
`USP drug classification
`http://www.genome.jp/kegg-bin/get_htext?br08302.keg
`Anatomical Therapeutic Chemical (ATC) classification
`http://www.genome.jp/kegg-bin/get_htext?br08303.keg
`Target-based classification of drugs
`http://www.genome.jp/kegg-bin/get_htext?br08310.keg
`Drug Classes
`http://www.genome.jp/kegg-bin/get_htext?br08330.keg
`25. UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)
`GHS Classification Tree
`http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
`26. ChEMBL
`LICENSE
`Access to the web interface of ChEMBL is made under the EBI's Terms of Use (http://www.ebi.ac.uk/Information/termsofuse.html). The ChEMBL data is
`made available on a Creative Commons Attribution-Share Alike 3.0 Unported License (http://creativecommons.org/licenses/by-sa/3.0/).
`http://www.ebi.ac.uk/Information/termsofuse.html
`
`Target Tree
`https://www.ebi.ac.uk/chembl/target/browser
`27. IUPHAR/BPS Guide to PHARMACOLOGY
`LICENSE
`The Guide to P